New insider activity at NewAmsterdam Pharma Company ( (NAMS) ) has taken place on March 6, 2025.
CAO Kooij Louise Frederika has recently sold 150,000 shares of NewAmsterdam Pharma Company stock, amounting to a total value of $3,055,500.
Recent Updates on NAMS stock
NewAmsterdam Pharma has seen recent positive developments that have influenced its stock price targets. Guggenheim analyst Debjit Chattopadhyay increased the price target due to the unique medicinal properties of obicetrapib, which is expected to overcome previous CETPi trial shortcomings. Scotiabank analyst George Farmer also raised the price target, citing the strong dataset from recent trials and the potential for regulatory filings in the U.S. and EU by the second half of 2025, which may lead to a potential acquisition. The company reported significant progress in its clinical trials, particularly with obicetrapib, and a successful $479 million financing, increasing its cash reserves. However, NewAmsterdam Pharma faces risks due to the significant influence of its principal shareholders, which could affect market price and potential acquisition opportunities.
More about NewAmsterdam Pharma Company
YTD Price Performance: -17.18%
Average Trading Volume: 939,523
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.36B
Questions or Comments about the article? Write to editor@tipranks.com